Reference : Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraph...
Scientific journals : Article
Human health sciences : Radiology, nuclear medicine & imaging
Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67
Belhocine, Tarik [> > > >]
Willems, Jacqueline mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine nucléaire >]
Rigo, Pierre mailto [Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire >]
Najjar, Fadi [> > > >]
Thiry, Albert mailto [Université de Liège - ULiège > > Anatomie pathologique >]
Quatresooz, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Hustinx, Roland mailto [Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire]
Nuclear Medicine Communications
Lippincott Williams & Wilkins
Yes (verified by ORBi)
[en] fluorodeoxyglucose positron emission tomography ; somatostatin receptor scintigraphy ; carcinoids ; proliferative activity
[en] We performed this study in order to evaluate the diagnostic accuracy of whole-body fluorodeoxyglucose positron emission tomography (FDG PET) imaging and somatostatin receptor scintigraphy (SRS) for localizing primary carcinoid tumours and evaluating the extent of the disease. A secondary aim was to correlate those findings with the histological characteristics of the lesions. FDG PET was performed in 17 patients and SRS in 16. All patients had pathologically proven carcinoids. All lesions were verified by histopathological analysis or by follow-up. Ki-67 and p53 expression were assessed as an indicator of the tumours' aggressiveness. FDG PET correctly identified 4/7 primary tumours and 8/11 metastatic spreads, as compared to six and 10 respectively, for SRS. Most tumours were typical carcinoids with low Ki-67 expression. No correlation was found between the histological features and the tracer's uptake. We conclude that SRS remains the modality of choice for evaluating patients with carcinoid tumours, regardless of their proliferative activity. FDG PET should be reserved to patients with negative results on SRS. ((C) 2002 Lippincott Williams Wilkins).

File(s) associated to this reference

Fulltext file(s):

Restricted access
Belhocine T et al, Nucl Med Comm 2002.pdfNo commentaryPublisher postprint285.86 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.